Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes
New York, NY
Friday, April 15, 2011
8:15 AM - 4:00 PM
Assessment of Needs
IAS–USA has expanded its mission to include activities that relate to the management of viral infections other than HIV. The first phase of these efforts will focus on hepatitis C virus (HCV) infection. Rapid advances in treatment are anticipated with the introduction of direct-acting antivirals (DAAs) to the HCV treatment paradigm. With the projected large increase in the number of patients who will require HCV treatment in the near future, clinicians who are experts in the complexities of antiretroviral management are uniquely well positioned to join our hepatology and gastroenterology colleagues in providing care for these patients, in what promises to be an exciting new era in HCV care.
Conflicts of Interest
Information regarding financial relationships with commercial companies that have interests in the content discussed, is obtained from all parties with control over the activity content (ie, co-chairs, faculty, and IAS–USA staff), and any real or apparent conflicts of interest of those parties are resolved prior to the activity being delivered. Financial affiliations of all those parties are published in the course syllabus. Individuals who refuse to disclose financial interests may not participate in the CME activity.
Who Should Attend
This course is designed for physicians and other health care practitioners who are experienced in the principles of complex chemotherapy (eg, antiretroviral therapy) and are actively treating or will be treating patients with HCV infection.
Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.
Upon completion of the IAS–USA viral hepatitis course, participants will be able to:
- Describe HCV replication and its impact on drug development and treatment strategies
- List key data from clinical trials of direct-acting antivirals in patients with HCV infection who are treatment naive or who have not responded to HCV treatment
- Discuss the mechanisms of HCV resistance
- Implement the treatment plans for HCV-infected patients that consider
- Clinical trial data on the efficacy and safety of directly acting antivirals
- Appropriate screening
- Monitoring for and definition of response
- Potential drug-drug interactions
- Management of adverse effects of treatment
- Data that are still needed to be able to best utilize current and future HCV treatments
- Describe the principles of managing liver disease, including staging and recommendations for monitoring for hepatocellular carcinoma.
Continuing Education Credits
The IAS–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The IAS–USA designates this educational activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In the interest of an objective, balanced, and scientifically rigorous CME program, educational grants are pooled to support this activity. We gratefully acknowledge the below commercial companies for their contributions.
Merck & Co, Inc
Requests for additional educational grants have been made to commercial companies with competing products. Information on additional grant supporters will be posted on the IAS–USA website as it becomes available.